| Literature DB >> 31991299 |
Rahul Valsaraj1, Awadhesh Kumar Singh2, Kalyan Kumar Gangopadhyay3, Biswajit Ghoshdastidar4, Ghanshyam Goyal5, Masood Batin6, Dibyendu Mukherjee7, Upal Sengupta8, Sanjay Chatterjee9, Nilanjan Sengupta10.
Abstract
AIM: The definition and management of asymptomatic hyperuricemia has been an area of controversy for many decades. Debate persists regarding the benefit of treating all cases of asymptomatic hyperuricemia and hence, unsurprisingly there are no clear clinical practice guidelines from our country. PARTICIPANTS: Ten members consisting of eminent physicians, endocrinologists, nephrologist and a rheumatologist were selected by the Integrated Diabetes & Endocrine Academy (IDEA) for a closed meeting with the aim to come to a consensus. EVIDENCE: A literature search was performed using PubMed and Cochrane library following which published articles in indexed peer review journals were selected. CONSENSUS PROCESS: Each participant voiced their opinion after reviewing the available data and a consensus was reached after three meetings by voting.Entities:
Keywords: Hyperuricemia; Urate lowering therapy; Uric acid
Mesh：
Year: 2020 PMID： 31991299 DOI： 10.1016/j.dsx.2020.01.007
Source DB: PubMed Journal: Diabetes Metab Syndr ISSN： 1871-4021